↓ Skip to main content

Dove Medical Press

Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents

Overview of attention for article published in OncoTargets and therapy, August 2011
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)

Mentioned by

twitter
1 X user
patent
3 patents
facebook
1 Facebook page

Citations

dimensions_citation
45 Dimensions

Readers on

mendeley
79 Mendeley
Title
Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents
Published in
OncoTargets and therapy, August 2011
DOI 10.2147/ott.s20257
Pubmed ID
Authors

Mohammad K Khan, Niloufer Khan, Alex Almasan, Roger Macklis

Abstract

The incidence of melanoma is rising. The primary initial treatment for melanoma continues to be wide local excision of the primary tumor and affected lymph nodes. Exceptions to wide local excision include cases where surgical excision may be cosmetically disfiguring or associated with increased morbidity and mortality. The role of definitive or adjuvant radiotherapy has largely been relegated to palliative measures because melanoma has been viewed as a prototypical radiotherapy-resistant cancer. However, the emerging clinical and radiobiological data summarized here suggests that many types of effective radiation therapy, such as radiosurgery for melanoma brain metastases, plaque brachytherapy for uveal melanoma, intensity modulated radiotherapy for melanoma of the head and neck, and adjuvant radiotherapy for selected high-risk, node-positive patients can improve outcomes. Similarly, although certain chemotherapeutic agents and biologics have shown limited responses, long-term control for unresectable tumors or disseminated metastatic disease has been rather disappointing. Recently, several powerful new biologics and treatment combinations have yielded new hope for this patient group. The recent identification of several clinically linked melanoma gene mutations involved in mitogen-activated protein kinase (MAPK) pathway such as BRAF, NRAS, and cKIT has breathed new life into the drive to develop more effective therapies. Some of these new therapeutic approaches relate to DNA damage repair inhibitors, cellular immune system activation, and pharmacological cell cycle checkpoint manipulation. Others relate to the investigation of more effective targeting and dosing schedules for underutilized therapeutics, such as radiotherapy. This paper summarizes some of these new findings and attempts to give some context to the renaissance in melanoma therapeutics and the potential role for multimodality regimens, which include certain types of radiotherapy as aids to locoregional control in sensitive tissues.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 3%
Poland 1 1%
Unknown 76 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 15 19%
Researcher 10 13%
Student > Ph. D. Student 8 10%
Other 7 9%
Student > Master 6 8%
Other 17 22%
Unknown 16 20%
Readers by discipline Count As %
Medicine and Dentistry 25 32%
Agricultural and Biological Sciences 20 25%
Biochemistry, Genetics and Molecular Biology 7 9%
Nursing and Health Professions 2 3%
Computer Science 1 1%
Other 4 5%
Unknown 20 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 December 2019.
All research outputs
#7,777,586
of 25,371,288 outputs
Outputs from OncoTargets and therapy
#417
of 3,016 outputs
Outputs of similar age
#42,082
of 130,319 outputs
Outputs of similar age from OncoTargets and therapy
#1
of 1 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 130,319 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them